© AbbVie Inc. All rights reserved.In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.
Featured Posts
Getting the balance right - Even as their clients are trying to make clinical trials more diverse and equitable, agencies are continuing their DE&I efforts to build a culture where diverse talent is welcomed.
Q&A: Considerations sponsors should make when implementing BYOD strategies in decentralized/hybrid trials - Besides reducing the burden of participation, sponsors benefit from lower costs and faster timelines. In addition, when patients are more engaged, patient protocol compliance increases.
Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.
Among updates from several pharma companies, Sanofi CEO Paul Hudson presented the company’s outlook for the new year, highlighting upcoming milestones and achievements that mark what he called the “new Sanofi.”
Pfizer forecasted stable growth in the coming years, driven by a strong product push to cushion its non-COVID business and exclusivity losses, according to company chairman and Chief Executive Officer Albert Bourla, M.D., Monday.
AbbVie Inc. on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira.
Bayer predicted on Tuesday its experimental drug against dangerous blood clots could make more than 5 billion euros ($5.4 billion) in peak annual sales, as the company seeks to revive a share price that has drawn interest from activist investors.
BioNTech SE has agreed to acquire the British artificial intelligence (AI) startup InstaDeep for up to 562 million pounds ($682 million) to speed up its biotech research beyond COVID shots.
The American Academy of Pediatrics (AAP) on Monday recommended use of weight-loss drugs in children ages 12 years or older for treatment of obesity, which impacts about 14.4 million kids and adolescents in the United States and can lead to serious health complications.
Ocugen Inc. said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd. met the main goals of a trial in the United States.
The Omicron-adapted COVID-19 vaccine booster developed by Pfizer Inc. and BioNTech SE sharply reduced hospitalizations among older patients, Israeli researchers said on Monday, in some of the first evidence of the jab’s real-world effectiveness.
